Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

→ Corey Good­man‘s CD47 start­up ALX On­col­o­gy has cinched two fast track des­ig­na­tions from the FDA for its lead can­di­date, ALX148 — for the first-line treat­ment of pa­tients with head and neck squa­mous cell car­ci­no­ma (HN­SCC), and for the sec­ond-line treat­ment of pa­tients with HER2-pos­i­tive gas­tric or gas­troe­sophageal junc­tion (gas­tric/GEJ) car­ci­no­ma. Des­ig­na­tions were grant­ed based on a Phase I clin­i­cal of ALX148 in com­bi­na­tion with pem­brolizum­ab and trastuzum­ab. This comes af­ter the ven­BIO-backed com­pa­ny snagged a $105 mil­lion mega-round last week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER